Difference between revisions of "Template:Antithrombotics"
Jump to navigation
Jump to search
blackwiki>Lukashenk0 m |
|||
| Line 22: | Line 22: | ||
| group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | | group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | ||
| list2 = | | list2 = | ||
| − | * | + | * [[Thienopyridine]]s |
** [[Clopidogrel]] | ** [[Clopidogrel]] | ||
** [[Prasugrel]] | ** [[Prasugrel]] | ||
** [[Ticlopidine]] | ** [[Ticlopidine]] | ||
| − | * | + | * [[Nucleotide]]/[[nucleoside]] analogs |
** [[Cangrelor]] | ** [[Cangrelor]] | ||
** [[Elinogrel]] | ** [[Elinogrel]] | ||
| Line 48: | Line 48: | ||
| group5 = [[Thromboxane inhibitors]] | | group5 = [[Thromboxane inhibitors]] | ||
| list5 = | | list5 = | ||
| − | * | + | * [[Thromboxane synthase inhibitors]] |
** [[Dipyridamole]] ([[Acetylsalicylic acid/dipyridamole|+Aspirin]]) | ** [[Dipyridamole]] ([[Acetylsalicylic acid/dipyridamole|+Aspirin]]) | ||
** [[Picotamide]] | ** [[Picotamide]] | ||
| − | * | + | * [[Thromboxane receptor antagonist|Receptor antagonist]]s |
** [[Terutroban]]<sup>†</sup> | ** [[Terutroban]]<sup>†</sup> | ||
| Line 74: | Line 74: | ||
| group2 = [[Vitamin K antagonist]]s<br />(inhibit [[Thrombin|II]], [[Factor VII|VII]], [[Factor IX|IX]], [[Factor X|X]]) | | group2 = [[Vitamin K antagonist]]s<br />(inhibit [[Thrombin|II]], [[Factor VII|VII]], [[Factor IX|IX]], [[Factor X|X]]) | ||
| list2 = | | list2 = | ||
| − | * | + | * [[Coumarin]]s: [[Acenocoumarol]] |
* [[Coumatetralyl]] | * [[Coumatetralyl]] | ||
* [[Dicoumarol]] | * [[Dicoumarol]] | ||
| Line 80: | Line 80: | ||
* [[Phenprocoumon]] | * [[Phenprocoumon]] | ||
* [[Warfarin]]<sup>#</sup> | * [[Warfarin]]<sup>#</sup> | ||
| − | * | + | * [[1,3-Indandione]]s: [[Clorindione]] |
* [[Diphenadione]] | * [[Diphenadione]] | ||
* [[Phenindione]] | * [[Phenindione]] | ||
| − | * | + | * Other: [[Tioclomarol]] |
| group3 = [[Factor Xa]] inhibitors<br />(with some II inhibition) | | group3 = [[Factor Xa]] inhibitors<br />(with some II inhibition) | ||
| Line 91: | Line 91: | ||
| group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | | group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | ||
| list1 = | | list1 = | ||
| − | * | + | * [[Low molecular weight heparin]] |
** [[Bemiparin sodium|Bemiparin]] | ** [[Bemiparin sodium|Bemiparin]] | ||
** [[Certoparin sodium|Certoparin]] | ** [[Certoparin sodium|Certoparin]] | ||
| Line 100: | Line 100: | ||
** [[Reviparin sodium|Reviparin]] | ** [[Reviparin sodium|Reviparin]] | ||
** [[Tinzaparin sodium|Tinzaparin]] | ** [[Tinzaparin sodium|Tinzaparin]] | ||
| − | * | + | * [[Oligosaccharide]]s |
** [[Fondaparinux]] | ** [[Fondaparinux]] | ||
** [[Idraparinux]] | ** [[Idraparinux]] | ||
| − | * | + | * [[Heparinoid]]s |
** [[Danaparoid]] | ** [[Danaparoid]] | ||
** [[Dermatan sulfate]] | ** [[Dermatan sulfate]] | ||
| Line 110: | Line 110: | ||
| group2 = [[Direct Xa inhibitor]]s | | group2 = [[Direct Xa inhibitor]]s | ||
| list2 = | | list2 = | ||
| − | * | + | * Xabans |
** [[Apixaban]] | ** [[Apixaban]] | ||
** [[Betrixaban]] | ** [[Betrixaban]] | ||
| Line 121: | Line 121: | ||
| group5 = [[Direct thrombin inhibitor|Direct thrombin (IIa) inhibitor]]s | | group5 = [[Direct thrombin inhibitor|Direct thrombin (IIa) inhibitor]]s | ||
| list5 = | | list5 = | ||
| − | * | + | * [[Direct_thrombin_inhibitor#Bivalent|Bivalent]]: [[Hirudin]] |
** [[Bivalirudin]] | ** [[Bivalirudin]] | ||
** [[Desirudin]] | ** [[Desirudin]] | ||
** [[Lepirudin]] | ** [[Lepirudin]] | ||
| − | * | + | * [[Direct_thrombin_inhibitor#Univalent|Univalent]]: [[Argatroban]] |
* [[Dabigatran]] | * [[Dabigatran]] | ||
* [[Melagatran]]<sup>‡</sup> | * [[Melagatran]]<sup>‡</sup> | ||
| Line 142: | Line 142: | ||
| group3 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s | | group3 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s | ||
| list3 = | | list3 = | ||
| − | * | + | * [[Plasminogen activator]]s: [[recombinant tissue plasminogen activators|r-tPA]] |
** [[Tissue plasminogen activator|Alteplase]] | ** [[Tissue plasminogen activator|Alteplase]] | ||
** [[Reteplase]] | ** [[Reteplase]] | ||
** [[Tenecteplase]] | ** [[Tenecteplase]] | ||
| − | * | + | * UPA |
** [[Saruplase]] | ** [[Saruplase]] | ||
** [[Urokinase]] | ** [[Urokinase]] | ||
| Line 152: | Line 152: | ||
* [[Monteplase]] | * [[Monteplase]] | ||
* [[Streptokinase]]<sup>#</sup> | * [[Streptokinase]]<sup>#</sup> | ||
| − | * | + | *Other [[serine endopeptidase]]s: [[Ancrod]] |
* [[Brinase]] | * [[Brinase]] | ||
* [[Fibrinolysin]] | * [[Fibrinolysin]] | ||
Revision as of 22:56, 7 December 2014
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Antithrombotics|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Antithrombotics|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Antithrombotics|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.